H Takeuchi1, Y Yamamoto, H Kitano, T Enomoto. 1. Division of Otorhinolaryngology, Head and Neck Surgery, Department of Medicine of Sensorimotor Organs, Faculty of Medicine, Tottori University, Yonago, Japan. oto3175@grape.med.tottori-u.ac.jp
Abstract
BACKGROUND: Thymus- and activation-regulated chemokine (TARC), which is a CC chemokine receptor (CCR) 4 ligand with ability to recruit Th2 cells to inflammatory sites, is pathogenetically important in allergic rhinitis. Specific immunotherapy (IT), among the most effective therapies for allergic rhinitis, has incompletely understood mechanisms of action. TARC might be involved in some benefits of IT. METHODS: TARC in sera was assayed, obtained from 50 patients with house dust mite allergic rhinitis before and 1 year after beginning IT. Their ages ranged from 6 to 34 years (mean, 10), 30 were male and 20 were female. RESULTS: In patients whose nasal obstruction responded to IT, TARC decreased significantly with IT, while when response was defined in terms of sneezing or rhinorrhea, TARC did not change significantly. CONCLUSION: TARC might be an important target of IT in reducing obstructive allergic rhinitis.
BACKGROUND:Thymus- and activation-regulated chemokine (TARC), which is a CC chemokine receptor (CCR) 4 ligand with ability to recruit Th2 cells to inflammatory sites, is pathogenetically important in allergic rhinitis. Specific immunotherapy (IT), among the most effective therapies for allergic rhinitis, has incompletely understood mechanisms of action. TARC might be involved in some benefits of IT. METHODS:TARC in sera was assayed, obtained from 50 patients with house dust mite allergic rhinitis before and 1 year after beginning IT. Their ages ranged from 6 to 34 years (mean, 10), 30 were male and 20 were female. RESULTS: In patients whose nasal obstruction responded to IT, TARC decreased significantly with IT, while when response was defined in terms of sneezing or rhinorrhea, TARC did not change significantly. CONCLUSION:TARC might be an important target of IT in reducing obstructive allergic rhinitis.
Authors: Bart van Hartingsveldt; Ivo P Nnane; Esther Bouman-Thio; Matthew J Loza; Alexa Piantone; Hugh M Davis; Kevin J Petty Journal: Br J Clin Pharmacol Date: 2013-05 Impact factor: 4.335